Evaluation of AX-158, a first-in-class Nck modulator, in patients with mild-to-moderate plaque psoriasis

Share:

D. Scott Batty, Jr., MD1*, Christopher VanDeusen, PhD1, Sandra Garcet, PhD2, James G. Krueger, MD PhD2